共价催化位点抑制剂对致癌性 K-Ras 的治疗靶向作用。
Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor.
机构信息
Department of Cancer Biology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 (USA); Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, 250 Longwood Avenue, Boston, MA 02115 (USA); Department of Chemistry and Chemical Biology, Harvard University, 12 Oxford Street, Cambridge, MA 02138 (USA).
出版信息
Angew Chem Int Ed Engl. 2014 Jan 3;53(1):199-204. doi: 10.1002/anie.201307387. Epub 2013 Nov 20.
Abstract
We report the synthesis of a GDP analogue, SML-8-73-1, and a prodrug derivative, SML-10-70-1, which are selective, direct-acting covalent inhibitors of the K-Ras G12C mutant relative to wild-type Ras. Biochemical and biophysical measurements suggest that modification of K-Ras with SML-8-73-1 renders the protein in an inactive state. These first-in-class covalent K-Ras inhibitors demonstrate that irreversible targeting of the K-Ras guanine-nucleotide binding site is potentially a viable therapeutic strategy for inhibition of Ras signaling.
摘要
我们报告了 GDP 类似物 SML-8-73-1 和前药衍生物 SML-10-70-1 的合成，它们是相对于野生型 Ras 对 K-Ras G12C 突变体具有选择性和直接作用的共价抑制剂。生化和生物物理测量表明，SML-8-73-1 对 K-Ras 的修饰使该蛋白处于无活性状态。这些首个类别的共价 K-Ras 抑制剂表明，不可逆地靶向 K-Ras 鸟嘌呤核苷酸结合位点可能是抑制 Ras 信号传导的一种可行的治疗策略。
相似文献
1
Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor.共价催化位点抑制剂对致癌性 K-Ras 的治疗靶向作用。
Angew Chem Int Ed Engl. 2014 Jan 3;53(1):199-204. doi: 10.1002/anie.201307387. Epub 2013 Nov 20.
2
In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C.SML-8-73-1 是一种致癌性 K-Ras G12C 活性位点抑制剂，本研究对其进行了原位选择性分析和晶体结构研究。
Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8895-900. doi: 10.1073/pnas.1404639111. Epub 2014 Jun 2.
3
H, N backbone assignment and comparative analysis of the wild type and G12C, G12D, G12V mutants of K-Ras bound to GDP at physiological pH.在生理pH值下，对与GDP结合的K-Ras野生型以及G12C、G12D、G12V突变体进行H、N主链归属及比较分析。
Biomol NMR Assign. 2020 Apr;14(1):1-7. doi: 10.1007/s12104-019-09909-7. Epub 2019 Aug 29.
4
Novel K-Ras G12C Switch-II Covalent Binders Destabilize Ras and Accelerate Nucleotide Exchange.新型 K-Ras G12C 开关 II 型共价结合物使 Ras 失稳并加速核苷酸交换。
J Chem Inf Model. 2018 Feb 26;58(2):464-471. doi: 10.1021/acs.jcim.7b00399. Epub 2018 Jan 31.
5
Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.用靶向非活性状态的小分子选择性抑制致癌性KRAS输出
Cancer Discov. 2016 Mar;6(3):316-29. doi: 10.1158/2159-8290.CD-15-1105. Epub 2016 Jan 6.
6
Selective inhibition of mutant Ras protein through covalent binding.通过共价键结合选择性抑制突变型 Ras 蛋白。
Angew Chem Int Ed Engl. 2014 Apr 7;53(15):3777-9. doi: 10.1002/anie.201400233. Epub 2014 Mar 3.
7
Drugging K-Ras through covalent inhibitors: Mission possible?通过共价抑制剂对 K-Ras 进行药物干预：可能实现吗？
Pharmacol Ther. 2019 Oct;202:1-17. doi: 10.1016/j.pharmthera.2019.06.007. Epub 2019 Jun 22.
8
Inhibition of Nonfunctional Ras.抑制无功能 Ras。
Cell Chem Biol. 2021 Feb 18;28(2):121-133. doi: 10.1016/j.chembiol.2020.12.012. Epub 2021 Jan 12.
9
Mutant-Specific Targeting of Ras G12C Activity by Covalently Reacting Small Molecules.通过共价反应小分子实现 Ras G12C 活性的突变体特异性靶向。
Cell Chem Biol. 2019 Oct 17;26(10):1338-1348. doi: 10.1016/j.chembiol.2019.07.005. Epub 2019 Aug 1.
10
High-frequency 94 GHz ENDOR characterization of the metal binding site in wild-type Ras x GDP and its oncogenic mutant G12V in frozen solution.野生型Ras x GDP及其致癌突变体G12V在冷冻溶液中金属结合位点的高频94 GHz电子核双共振表征。
Biochemistry. 2006 Jan 10;45(1):42-50. doi: 10.1021/bi051156k.
引用本文的文献
1
The complex journey of targeting RAS in oncology.肿瘤学中靶向RAS的复杂历程。
BMC Cancer. 2025 Jul 1;25(1):1053. doi: 10.1186/s12885-025-14033-y.
2
Evolution of structure-guided drug design strategies targeting mutations in codon 12 of KRAS.针对KRAS基因第12密码子突变的结构导向药物设计策略的演变
RSC Med Chem. 2025 May 26. doi: 10.1039/d5md00169b.
3
Structural insights, regulation, and recent advances of RAS inhibitors in the MAPK signaling cascade: a medicinal chemistry perspective.从药物化学角度看RAS抑制剂在MAPK信号级联中的结构见解、调控及最新进展
RSC Med Chem. 2025 Mar 5. doi: 10.1039/d4md00923a.
4
First molecules to reactivate RAS GTPase activity.首个重新激活RAS GTP酶活性的分子。
BMC Cancer. 2025 Jan 31;25(1):182. doi: 10.1186/s12885-025-13580-8.
5
Quantum-computing-enhanced algorithm unveils potential KRAS inhibitors.量子计算增强算法揭示潜在的KRAS抑制剂。
Nat Biotechnol. 2025 Jan 22. doi: 10.1038/s41587-024-02526-3.
6
New insights into protein-protein interaction modulators in drug discovery and therapeutic advance.药物发现与治疗进展中蛋白质-蛋白质相互作用调节剂的新见解。
Signal Transduct Target Ther. 2024 Dec 6;9(1):341. doi: 10.1038/s41392-024-02036-3.
7
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms.RAS 信号通路在肿瘤发生、癌症治疗和耐药机制中的作用。
J Hematol Oncol. 2024 Nov 9;17(1):108. doi: 10.1186/s13045-024-01631-9.
8
A noncanonical GTPase signaling mechanism controls exit from mitosis in budding yeast.一种非规范的 GTPase 信号机制控制芽殖酵母有丝分裂的退出。
Proc Natl Acad Sci U S A. 2024 Nov 5;121(45):e2413873121. doi: 10.1073/pnas.2413873121. Epub 2024 Oct 30.
9
Advances and Challenges in RAS Signaling Targeted Therapy in Leukemia.白血病中RAS信号通路靶向治疗的进展与挑战
Mol Cancer Ther. 2025 Jan 2;24(1):33-46. doi: 10.1158/1535-7163.MCT-24-0504.
10
Targeting Ras-, Rho-, and Rab-family GTPases via a conserved cryptic pocket.通过保守的隐匿口袋靶向 Ras-、Rho- 和 Rab 家族 GTPases。
Cell. 2024 Oct 31;187(22):6379-6392.e17. doi: 10.1016/j.cell.2024.08.017. Epub 2024 Sep 9.
本文引用的文献
1
Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling.小分子抑制 KRAS-PDEδ 相互作用可损害致癌 KRAS 信号传导。
Nature. 2013 May 30;497(7451):638-42. doi: 10.1038/nature12205. Epub 2013 May 22.
2
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.在肺癌中对受体酪氨酸激酶突变的功能分析确定了 ERBB2 的致癌细胞外结构域突变。
Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14476-81. doi: 10.1073/pnas.1203201109. Epub 2012 Aug 20.
3
Ras inhibition via direct Ras binding--is there a path forward?通过直接与 Ras 结合抑制 Ras——是否有前进的道路？
Bioorg Med Chem Lett. 2012 Sep 15;22(18):5766-76. doi: 10.1016/j.bmcl.2012.07.082. Epub 2012 Aug 2.
4
A comprehensive survey of Ras mutations in cancer.癌症中 Ras 突变的全面调查。
Cancer Res. 2012 May 15;72(10):2457-67. doi: 10.1158/0008-5472.CAN-11-2612.
5
Discovery of potent and selective covalent inhibitors of JNK.发现JNK的强效和选择性共价抑制剂。
Chem Biol. 2012 Jan 27;19(1):140-54. doi: 10.1016/j.chembiol.2011.11.010.
6
The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins.GDI 样溶解因子 PDEδ 维持 Ras 家族蛋白的空间组织和信号转导。
Nat Cell Biol. 2011 Dec 18;14(2):148-58. doi: 10.1038/ncb2394.
7
Therapeutic strategies for targeting ras proteins.靶向Ras蛋白的治疗策略。
Genes Cancer. 2011 Mar;2(3):359-72. doi: 10.1177/1947601911412376.
8
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer.COSMIC：在癌症体细胞突变目录中挖掘完整的癌症基因组。
Nucleic Acids Res. 2011 Jan;39(Database issue):D945-50. doi: 10.1093/nar/gkq929. Epub 2010 Oct 15.
9
A structure-guided approach to creating covalent FGFR inhibitors.一种用于创建共价FGFR抑制剂的结构导向方法。
Chem Biol. 2010 Mar 26;17(3):285-95. doi: 10.1016/j.chembiol.2010.02.007.
10
Hydrogen exchange mass spectrometry: what is it and what can it tell us?氢交换质谱法：它是什么，能告诉我们什么？
Anal Bioanal Chem. 2010 Jun;397(3):967-72. doi: 10.1007/s00216-010-3556-4. Epub 2010 Mar 1.
Zotero 插件